Robert Nunan uses his 15 years of academic and industry experience to lead a specialist team of scientists who design and apply human and murine immune assays to better understand how therapeutics can diminish immunosuppressive features of the TME. Before joining Charles River's Portishead Discovery site (formally KWS BioTest), Rob held postdoctoral positions at several academic institutions (Bristol University, Bath University, and Cardiff University) where he investigated biological mechanisms underlying tissue repair and regeneration. Rob received his PhD in neuroimmunology from the University of Southampton and discovered his love for drug discovery after working at Eli Lilly during his degree.
- Increased Osteopontin Levels in the Cerebrospinal Fluid of Patients With Multiple Sclerosis
- Microglial VPAC1R Mediates a Novel Mechanism of Neuroimmune-Modulation of Hippocampal Precursor Cells via IL-4 Release
- Pharmacy Operationalization of the Intralesional Oncolytic Immunotherapy Talimogene Laherparepvec